RecruitingNot ApplicableNCT05919342

Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY

Sponsor

NHS Greater Glasgow and Clyde

Enrollment

3,904 participants

Start Date

Dec 22, 2022

Study Type

INTERVENTIONAL

Conditions

Heart Failure Cardiovascular Diseases

Summary

This is an international prospective, multicentre, unblinded, randomised-controlled trial. The primary aim is to assess a targeted screening strategy to detect undiagnosed heart failure in high-risk patients.

Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This trial studies whether regular blood tests and heart scans can catch heart failure early in people who have never been diagnosed with it but are at high risk. You may be eligible if... - You are 40 years of age or older - You have two or more of these conditions: coronary artery disease, diabetes (type 1 or 2), permanent atrial fibrillation, previous stroke, peripheral artery disease, chronic kidney disease, regular use of water pills (loop diuretics) for more than 30 days, or COPD - You are able to give informed consent You may NOT be eligible if... - You have already been diagnosed with heart failure - You are currently on kidney dialysis - You have significant memory or thinking problems that prevent you from giving consent - The study doctor feels you are not a good fit for the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTNT-proBNP

Patients will undergo an NT-proBNP which will guide their future involvement within the study. Patients with an NT-proBNP of ≥125 pg/mL will undergo transthoracic echocardiogram along with a clinical assessment - any diagnosis of HF will result in patients undergoing referral for initiation of guideline directed medical therapy (for HF).